Abstract
Several years of experience have now accumulated in the targeting of anti-cancer agents so that we can take stock, identify problems and look for ways round them. Three major obstacles seem to limit present approaches. These are heterogeneity in the distribution of target molecules within the cancer cell population, the pharmacokinetic characteristics of macromolecules and host antibody response to foreign protein. An approach which we have been investigating uses antibodies or other vectors to carry enzymes which have no close human homologue to tumour sites. After clearing residual enzyme activity from the blood by one of several possible techniques, a relatively non-toxic prodrug is given. This prodrug is a substrate for the tumour located enzyme which results in the generation of a highly toxic molecule able to penetrate the tumour mass and cross cell membranes. Genetic engineering methods now offer the prospect of human immunoglobulins with tumour binding and catalytic sites having the potential to minimise host response. Whether this can be achieved depends on having antibodies with adequate specificity and our ability to develop enzyme-prodrug systems with the required characteristics. Early results encourage us to think progress can be made in this direction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
The first 'Bagshawe Lecture' was given at the Joint Meeting of the Association of Cancer Physicians and the British Association for Cancer Research at Glasgow on 10 April 1989. The title on that occasion was 'Whilst waiting for the human genome to be mapped'.
Rights and permissions
About this article
Cite this article
Bagshawe, K. The First Bagshawe lecture: Towards generating cytotoxic agents at cancer sites. Br J Cancer 60, 275–281 (1989). https://doi.org/10.1038/bjc.1989.270
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.270
This article is cited by
-
Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
European Journal of Nuclear Medicine and Molecular Imaging (2003)